Xeris Pharmaceuticals is based in Chicago. It has raised $200M in total funding. Latest round: IPO.
Xeris Pharmaceuticals funding overview
Xeris Pharmaceuticals is based in Chicago. Xeris Pharmaceuticals has raised $200M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in May 2017. The round record for Xeris Pharmaceuticals runs through 2017; nothing later has been disclosed. Investors on record include Redmile Group, Deerfield Management Company, Palmetto Partners, Wild Basin Investments, Asahi-Kasei Corporation, Bay City Capital and 1 others. 7 distinct backers are named across the disclosed rounds.
Xeris Pharmaceuticals at a glance
Total raised
$200M
Latest round
IPO
Latest round date
May 2017
Headquarters
Chicago
Notable investors
Redmile Group, Deerfield Management Company, Palmetto Partners, Wild Basin Investments, Asahi-Kasei Corporation, Bay City Capital, Merieux Développement
Frequently asked about Xeris Pharmaceuticals funding
How much has Xeris Pharmaceuticals raised?
Xeris Pharmaceuticals has raised $200M in total disclosed funding across the rounds on record.
Who has invested in Xeris Pharmaceuticals?
Redmile Group, Deerfield Management Company, Palmetto Partners, Wild Basin Investments, Asahi-Kasei Corporation, Bay City Capital are named among the investors backing Xeris Pharmaceuticals.
What was the latest Xeris Pharmaceuticals funding round?
The most recent disclosed round is an IPO, announced in May 2017.
Where is Xeris Pharmaceuticals based?
Xeris Pharmaceuticals is based in Chicago.
When did Xeris Pharmaceuticals last raise?
The last disclosed Xeris Pharmaceuticals round closed in May 2017 at IPO.
Round data for Xeris Pharmaceuticals is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Chicago and backer lists below.
